Brief Article
Copyright ©2009 The WJG Press and Baishideng.
World J Gastroenterol. Nov 28, 2009; 15(44): 5610-5619
Published online Nov 28, 2009. doi: 10.3748/wjg.15.5610
Table 1 The position, polymorphism and primer sequence in IL-2, IL-4 and IL-10 genes
SNP positionPolymorphismPrimer sequence 5’-3’PCR conditions
IL-2 -330T→GF: 5'-TATTCACATGTTCAGTGTAGTTCT-3'94°C, 48°C, 72°C for 1 min
R: 5'-ACATTAGCCCACACTTAGGT-3'
IL-4 -589C→TF: 5'-ACTAGGCCTCACCTGATACG-3'94°C, 57°C, 72°C for 30 s
R: 5'-GTTGTAATGCAGTCCTCCTG-3'
IL-10 -592A→CF: 5'-CCTAGGTCACAGTGACGTGG-3'94°C/30 s, 60°C/45 s, 72°C/60 s
R: 5'-GGTGAGCACTACCTGACTAGC-3'
Table 2 Polymorphism position, product size, restriction enzyme, digestion fragments in IL-2-330, IL-4-589 and IL-10-592
SNP positionProduct size (bp)Restriction enzymeDigestion fragments (bp)
IL-2-330 T/G150MaeI (Bio Basic Inc.)150
26 + 124
IL-4-589 T/C252BsmFI (New England BioLabs)252
60 + 192
IL-10-592 C/A412RsaI (Bio Basic Inc.)412
236 + 176
Table 3 HWE test for cytokines
LocusObserved homozygosity (%)
Expected homozygosity (%)
P value
Wild-type genotypeMutant genotypeWild-type genotypeMutant genotype
IL-2-33040.7914.0840.1413.43> 0.05
IFN-γ+87411.5535.0214.6538.10> 0.05
IL-4-5893.2550.546.9454.24> 0.05
IL-10-59242.6010.8343.4011.64> 0.05
IL-10-10821.0835.0210.9144.85< 0.05
Table 4 Polymorphisms of IL-2-330, IFN-γ+874, IL-10-1082 and -592 and IL-4-589 and HBV and HCV infection n (%)
Genotype alleleControls (n = 74)HCV infection (n = 55)HBV infection (n = 69)HBV/HCV coinfection (n = 79)χ2P
IL-2-330
TT22 (29.7)24 (43.6)33 (47.8)34 (43.0)
GG19 (25.7)6 (10.9)4 (5.8)10 (12.7)14.240.03
TG33 (44.6)25 (45.5)32 (46.4)35 (44.3)
T77 (52.0)73 (66.4)98 (71.0)103 (65.2)12.330.01
G71 (48.0)37 (33.6)40 (29.0)55 (34.8)
IFN-γ+874
TT7 (9.5)5 (9.1)9 (13.0)11 (13.9)
AA14 (18.9)23 (41.8)25 (36.2)35 (44.3)16.150.01
TA53 (71.6)27 (49.1)35 (50.7)33 (41.8)
T67 (45.3)37 (33.6)53 (38.4)55 (34.8)4.870.18
A81 (54.7)73 (66.4)85 (61.6)103 (65.2)
IL-10-1082
GG1 (1.4)2 (3.6)0 (0.0)0 (0.0)
AA16 (21.6)21 (38.2)27 (39.1)33 (41.8)13.050.04
GA57 (77.0)32 (58.2)42 (60.9)46 (58.2)
G59 (39.9)36 (32.7)42 (30.4)46 (29.1)4.650.20
A89 (60.1)74 (67.3)96 (69.6)112 (70.9)
IL-10-592
AA34 (45.9)20 (36.4)29 (42.0)35 (44.3)
CC9 (12.2)6 (10.9)9 (13.0)6 (7.6)2.830.83
AC31 (41.9)29 (52.7)31 (44.9)38 (48.1)
A99 (66.9)69 (62.7)89 (64.5)108 (68.4)1.100.78
C49 (33.1)41 (37.3)49 (35.5)50 (31.6)
IL-4-589
CC5 (6.8)1 (1.8)1 (1.4)2 (2.5)
TT38 (51.4)28 (50.9)35 (50.7)39 (49.4)4.410.62
CT31 (41.9)26 (47.3)33 (47.8)38 (48.1)
C41 (27.7)28 (25.5)35 (25.4)42 (26.6)0.260.97
T107 (72.3)82 (74.5)103 (74.6) 116 (73.4)
Table 5 Polymorphisms of IL-2-330, IFN-γ+874, IL-4-589, IL-10-1082 and -592 and clinical outcome n (%)
GenotypeControl (n = 74)Mild CH (n = 122)Moderate/severe CH (n = 57)Cirrhosis (n = 24)χ2P
IL-2-330
TT22 (29.7)54 (44.3)23 (40.4)13 (54.2)
GG19 (25.7)14 (11.4)6 (10.5)1 (4.2)13.460.04
TG33 (44.6)54 (44.3)28 (49.1)10 (41.7)
T77 (52.0)163 (66.8)74 (64.9)36 (75.0)11.690.01
G71 (48.0)81 (33.2)40 (35.0)12 (25.0)
IFN-γ+874
TT8 (10.8)14 (11.5)5 (8.8)4 (16.7)
AA14 (18.9)48 (39.3)26 (45.6)9 (37.5)14.780.02
TA52 (70.3)60 (49.2)26 (45.6)11 (45.8)
T68 (45.9)90 (36.9)36 (31.6)19 (39.6)5.680.13
A80 (54.1)154 (63.1)78 (68.4)29 (60.4)
IL-10-1082
GG1 (1.4)1 (0.8)1 (1.8)0 (0.0)
AA16 (21.6)44 (36.1)24 (42.1)13 (54.2)11.400.07
GA57 (77.0)77 (63.1)32 (56.1)11 (45.8)
G59 (39.9)79 (32.4)34 (29.8)11 (22.9)5.850.12
A89 (60.1)165 (67.6)80 (70.2)37 (77.1)
IL-10-592
AA34 (45.9)51 (41.8)22 (38.6)11 (45.8)
CC9 (12.2)11 (9.0)8 (14.0)2 (8.3)2.500.87
AC31 (41.9)60 (49.2)27 (47.4)11 (45.8)
A98 (66.2)163 (66.8)71 (62.3)33 (68.8)0.920.82
C50 (33.8)81 (33.2)43 (37.7)15 (31.3)
IL-4-589
CC3 (4.0)3 (2.4)3 (5.3)0 (0.0)
TT38 (51.4)69 (54.8)24 (42.1)11 (45.8)4.580.60
CT33 (44.6)54 (42.9)30 (52.6)13 (54.2)
C39 (26.4)58 (23.8)36 (31.6)13 (27.1)2.460.48
T109 (73.6)186 (76.2)78 (68.4)35 (72.9)
Table 6 Polymorphisms of IL-2-330, IFN-γ+874, IL-4 -589 and IL-10-1082 and -592 and HCV RNA and ALT level n (%)
HCV RNA -HCV RNA +χ2PALT < 80 U/LALT ≥ 80 U/Lχ2P
IL-2-330
TT29 (37.2)39 (37.1)102 (41.8)11 (33.3)
GG14 (17.9)14 (13.3)0.830.6635 (14.3)4 (12.1)1.350.51
TG35 (44.9)52 (49.5)107 (43.9)18 (54.5)
T93 (59.6)130 (61.9)0.200.66311 (63.7)40 (60.0)0.240.62
G63 (40.4)80 (38.1)177 (36.3)26 (39.4)
IFN-γ+874
TT13 (16.7)10 (9.5)29 (11.9)3 (9.1)
AA28 (35.9)45 (42.9)2.360.3185 (34.8)12 (36.4)0.230.89
TA37 (47.4)50 (47.6)130 (53.3)18 (54.5)
T63 (40.4)70 (33.3)1.920.17188 (38.5)24 (36.4)0.120.74
A93 (59.6)140 (66.7)300 (61.5)42 (63.6)
IL-10-1082
GG1 (1.3)2 (1.9)3 (1.2)0 (0.0)
AA14 (17.9)44 (41.9)12.270.0081 (33.2)16 (48.5)3.250.20
GA63 (80.8)59 (56.2)160 (65.6)17 (51.5)
G91 (58.3)147 (70.0)5.360.02166 (34.0)17 (25.8)1.790.18
A65 (41.7)63 (128)322 (66.0)49 (74.2)
IL-10-592
AA41 (52.6)44 (41.9)110 (45.1)8 (24.2)
CC6 (7.7)11 (10.5)2.100.3527 (11.1)3 (9.1)6.320.04
AC31 (39.7)50 (47.6)107 (43.9)22 (66.7)
A113 (72.4)138 (65.7)1.880.17327 (67.0)38 (57.6)2.300.09
C43 (27.6)72 (34.3)161 (33.0)28 (42.4)
IL-4-589
CC3 (3.8)5 (4.8)6 (2.5)3 (9.1)
TT48 (61.5)55 (52.4)1.530.47132 (54.1)8 (24.2)12.460.02
CT27 (34.6)45 (42.9)106 (43.4)22 (66.7)
C33 (21.2)55 (26.2)1.240.27118 (24.2)28 (42.4)9.970.00
T123 (78.8)155 (73.8)370 (75.8)38 (57.6)